Persistent release of IL-1s from skin is associated with systemic cardio-vascular disease, emaciation and systemic amyloidosis: The potential of anti-IL-1 therapy for systemic inflammatory diseases

PLoS ONE

Volumn 9, Issue 8, 2014, Pages

  Yamanaka, Keiichi ^a   Nakanishi, Takehisa ^a   Saito, Hiromitsu ^a   Maruyama, Junko ^b   Isoda, Kenichi ^a   Yokochi, Ayumu ^a   Imanaka Yoshida, Kyoko ^a   Tsuda, Kenshiro ^a   Kakeda, Masato ^a   Okamoto, Ryuji ^a   Fujita, Satoshi ^a   Iwakura, Yoichiro ^c   Suzuki, Noboru ^a   Ito, Masaaki ^a   Maruyama, Kazuo ^a   Gabazza, Esteban C ^a   Yoshida, Toshimichi ^a   Shimaoka, Motomu ^a   Mizutani, Hitoshi ^a  

^a MIE UNIVERSITY   (Japan)

^b SUZUKA UNIVERSITY OF MEDICAL SCIENCE   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; CYTOKINE; INTERLEUKIN 1; NEUTRALIZING ANTIBODY;

AMYLOIDOSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BLOOD; CARDIOVASCULAR DISEASE; COMPUTER ASSISTED TOMOGRAPHY; EMACIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOLOGY; MOUSE; SECRETION (PROCESS); SKIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TRANSGENIC MOUSE;

AMYLOIDOSIS; ANIMALS; ANTIBODIES, NEUTRALIZING; CARDIOVASCULAR DISEASES; CHOLESTEROL; CYTOKINES; EMACIATION; ENZYME-LINKED IMMUNOSORBENT ASSAY; INTERLEUKIN-1; MICE; MICE, TRANSGENIC; SKIN; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TOMOGRAPHY, X-RAY COMPUTED;

EID: 84905913044     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0104479     Document Type: Article

References (26)

1. Davidovici BB, Sattar N, Prinz J, Puig L, Emery P, et al. (2010) Psoriasis and systemic inflammatory diseases: potential mechanistic links between skin disease and co-morbid conditions. The Journal of investigative dermatology 130: 1785-1796.
2. Fine JD, Hall M, Weiner M, Li KP, Suchindran C (2008) The risk of cardiomyopathy in inherited epidermolysis bullosa. Br J Dermatol 159: 677-682.
3. Fine JD, Johnson LB, Weiner M, Stein A, Cash S, et al. (2004) Inherited epidermolysis bullosa and the risk of death from renal disease: experience of the National Epidermolysis Bullosa Registry. American journal of kidney diseases: the official journal of the National Kidney Foundation 44: 651-660.
4. Samuelov L, Sarig O, Harmon RM, Rapaport D, Ishida-Yamamoto A, et al. (2013) Desmoglein 1 deficiency results in severe dermatitis, multiple allergies and metabolic wasting. Nature genetics 45: 1244-1248.
5. Watanabe N and Kobayashi Y (1994) Selective release of a processed form of interleukin 1 alpha. Cytokine 6: 597-601. (Pubitemid 24363177)
6. Afonina IS, Tynan GA, Logue SE, Cullen SP, Bots M, et al. (2011) Granzyme B-dependent proteolysis acts as a switch to enhance the proinflammatory activity of IL-1alpha. Molecular cell 44: 265-278.
7. Konishi H, Tsutsui H, Murakami T, Yumikura-Futatsugi S, Yamanaka K, et al. (2002) IL-18 contributes to the spontaneous development of atopic dermatitis-like inflammatory skin lesion independently of IgE/stat6 under specific pathogen-free conditions. Proceedings of the National Academy of Sciences of the United States of America 99: 11340-11345. (Pubitemid 34920927)
8. Herrero L, Shapiro H, Nayer A, Lee J, Shoelson SE (2010) Inflammation and adipose tissue macrophages in lipodystrophic mice. Proceedings of the National Academy of Sciences of the United States of America 107: 240-245.
9. Dinarello CA, Simon A, van der Meer JW (2012) Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nature reviews Drug discovery 11: 633-652.
10. Ridker PM, Thuren T, Zalewski A, Libby P (2011) Interleukin-1beta inhibition and the prevention of recurrent cardiovascular events: rationale and design of the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS). American heart journal 162: 597-605.
11. Tabas I (2010) Macrophage death and defective inflammation resolution in atherosclerosis. Nature reviews Immunology 10: 36-46.
12. Peiris JS, Cheung CY, Leung CY, Nicholls JM (2009) Innate immune responses to influenza A H5N1: friend or foe? Trends in immunology 30: 574-584.
13. Tsoli M, Robertson G (2012) Cancer cachexia: malignant inflammation, tumorkines, and metabolic mayhem. Trends in endocrinology and metabolism: TEM.
14. Yamanaka K, Tanaka M, Tsutsui H, Kupper TS, Asahi K, et al. (2000) Skin specific caspase-1 transgenic mouse expresses cutaneous apoptosis and pre-endotoxin shock condition with a high serum level of IL-18. Journal of Immunology 165: 997-1003. (Pubitemid 30484769)
15. Green H, Meuth M (1974) An established pre-adipose cell line and its differentiation in culture. Cell 3: 127-133.
16. Maruyama J, Yokochi A, Maruyama K, Nosaka S (1999) Acetylcholine-induced endothelium-derived contracting factor in hypoxic pulmonary hypertensive rats. J Appl Physiol 86: 1687-1695. (Pubitemid 29230317)
17. Nishioka T, Suzuki M, Onishi K, Takakura N, Inada H, et al. (2007) Eplerenone attenuates myocardial fibrosis in the angiotensin II-induced hypertensive mouse: involvement of tenascin-C induced by aldosterone-mediated inflammation. Journal of cardiovascular pharmacology 49: 261-268. (Pubitemid 46855118)
18. Horai R, Asano M, Sudo K, Kanuka H, Suzuki M, et al. (1998) Production of mice deficient in genes for interleukin (IL)-1alpha, IL-1beta, IL-1alpha/beta, and IL-1 receptor antagonist shows that IL-1beta is crucial in turpentine-induced fever development and glucocorticoid secretion. The Journal of experimental medicine 187: 1463-1475. (Pubitemid 28215405)
19. Merhi-Soussi F, Kwak BR, Magne D, Chadjichristos C, Berti M, et al. (2005) Interleukin-1 plays a major role in vascular inflammation and atherosclerosis in male apolipoprotein E-knockout mice. Cardiovascular research 66: 583-593. (Pubitemid 40725770)
20. Akdogan A, Calguneri M, Yavuz B, Arslan EB, Kalyoncu U, et al. (2006) Are familial Mediterranean fever (FMF) patients at increased risk for atherosclerosis? Impaired endothelial function and increased intima media thickness are found in FMF. Journal of the American College of Cardiology 48: 2351-2353. (Pubitemid 44855439)
21. Yu AP, Tang J, Xie J, Wu EQ, Gupta SR, et al. (2009) Economic burden of psoriasis compared to the general population and stratified by disease severity. Current medical research and opinion 25: 2429-2438.
22. Ahlehoff O, Skov L, Gislason G, Lindhardsen J, Kristensen SL, et al. (2013) Cardiovascular disease event rates in patients with severe psoriasis treated with systemic anti-inflammatory drugs: a Danish real-world cohort study. Journal of internal medicine 273: 197-204.
23. Retief CR, Malkinson FD, Pearson RW (1999) Two familial cases of epidermolysis bullosa simplex successfully treated with tetracycline. Archives of dermatology 135: 997-998. (Pubitemid 29382453)
24. Veien NK, Buus SK (2000) Treatment of epidermolysis bullosa simplex (EBS) with tetracycline. Archives of dermatology 136: 424-425. (Pubitemid 30149127)
25. Wally V, Lettner T, Peking P, Peckl-Schmid D, Murauer EM, et al. (2013) The pathogenetic role of IL-1beta in severe epidermolysis bullosa simplex. The Journal of investigative dermatology 133: 1901-1903.
26. Samavedam UK, Kalies K, Scheller J, Sadeghi H, Gupta Y, et al. (2013) Recombinant IL-6 treatment protects mice from organ specific autoimmune disease by IL-6 classical signalling-dependent IL-1ra induction. Journal of autoimmunity 40: 74-85.